BeyondSpring Inc. has launched an at-the-market equity offering of up to $11.94 million as the biotechnology company restructures funding for its late-stage lung cancer program and advances a strategic transaction involving its China operations.
A prospectus supplement filed with the Securities and Exchange Commission on Sept. 29 allows BeyondSpring to sell up to 9.2 million ordinary shares through Citizens JMP Securities. The shares may be sold periodically at prevailing market prices, with Citizens entitled to commissions of up to 3% of gross proceeds. BeyondSpring said it intends to use the net proceeds for research and development and general corporate purposes.
The equity offering comes alongside a strategic transaction under which BeyondSpring agreed to transfer its entire interest in BeyondSpring Ltd., a British Virgin Islands subsidiary that indirectly holds its stake in Dalian Wanchunbulin Pharmaceuticals, to Biolin Investment Limited. The agreement, entered into Sept. 28 according to the prospectus, makes the China portion of the global DUBLIN-4 Phase 3 trial part of the consideration for the transfer rather than requiring BeyondSpring to fund that portion independently.
DUBLIN-4 is planned as a 442-patient randomized Phase 3 study evaluating plinabulin combined with docetaxel against docetaxel alone in patients with advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations whose disease has progressed after prior immune checkpoint inhibitor and platinum-based chemotherapy. About 221 patients are expected to be enrolled in China. BeyondSpring will retain global rights to plinabulin outside Greater China and receive data generated from the China portion for incorporation into its broader regulatory strategy.
The transaction changes the funding structure of the development program at a time when BeyondSpring has limited cash resources. The company reported $2.7 million in cash and cash equivalents attributable to continuing operations at June 30, 2026, alongside $3.8 million in short-term investments. It reported a $12.4 million net loss for the first six months of 2026 and said it had no product revenue.
The China transaction is therefore separate from, but complementary to, the new equity offering. The ATM gives BeyondSpring access to additional capital at its discretion, while the strategic arrangement shifts responsibility for the China portion of DUBLIN-4 to Biolin. The company said the arrangement is expected to substantially reduce its cash requirements for the global trial while preserving access to China clinical data.
BeyondSpring also announced that the U.S. Food and Drug Administration granted Fast Track designation to plinabulin in combination with docetaxel for the targeted post-immune-checkpoint-inhibitor setting. Fast Track applies to advanced or metastatic non-squamous NSCLC without actionable genomic alterations following progression on prior anti-PD-(L)1 antibody therapy and platinum-based chemotherapy, covering second- and third-line treatment.
Fast Track designation is intended to facilitate development and regulatory review for drugs addressing serious conditions and unmet medical needs, but it does not constitute FDA approval or establish that a drug will ultimately demonstrate efficacy or safety sufficient for approval.
The DUBLIN-4 study has overall survival as its primary endpoint, with progression-free survival and objective response rate as secondary endpoints. The trial includes a planned interim analysis after 221 progression-free survival events.
BeyondSpring is also seeking additional capital through the ATM facility as it continues development of plinabulin. The company had previously reported positive Phase 3 findings from DUBLIN-3 and is positioning DUBLIN-4 as its confirmatory global study. Its earlier disclosures said more than 700 cancer patients had been treated with plinabulin across clinical programs.
The latest filings also come shortly after BeyondSpring received a Nasdaq notice over its share price. The company said in its prospectus that its shares had remained below Nasdaq’s $1 minimum bid-price requirement for 30 consecutive business days as of Sept. 17, giving it until March 16, 2027, to regain compliance under the initial compliance period.
The combination of the new ATM facility, the China strategic transaction and the FDA Fast Track designation gives BeyondSpring multiple developments around its effort to move DUBLIN-4 forward while addressing the financing demands of the program.
